David Kavanagh: Largely on the basis of these results and related IARC research, World Health Organization recently recommended supporting a single-dose schedule for HPV vaccination
David Kavanagh, Head of Human Resources Office International Agency for Research on Cancer / World Health Organization, shared on LinkedIn:
“IARC – International Agency for Research on Cancer / World Health Organization scientists are conducting research that is advancing these three areas, such as studying the immune response to different numbers of doses of HPV vaccine.
Thanks to these evaluations, it is now known that a single dose of vaccine offers adequate protection to neutralize the virus and that immunogenicity of a single dose remains high even 10 years after vaccination.
Largely on the basis of these results and related IARC research, World Health Organization recently recommended supporting a single-dose schedule for HPV vaccination.”
Visit the article website.
Source: David Kavanagh/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023